Peninsula Pharmaceuticals Incorporated

Peninsula Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the licensing, development, and commercialization anti-infective therapies for the treatment of patients with life-threatening infections for the North American and European markets.

Peninsula's lead product candidate, doripenem, is a broad-spectrum antibiotic and a new member of the carbapenem class of beta-lactam antibiotics. Peninsula is currently evaluating doripenem in six Phase III clinical trials. In addition, doripenem received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of nosocomial pneumonia, including ventilator-associated pneumonia (VAP).

Peninsula Pharmaceuticals was acquired by Johnson & Johnson, a global manufacturer of health care products, as well as a provider of related services, for the consumer, pharmaceutical, and medical devices and diagnostics markets.

Peninsula Pharmaceuticals, Inc. is a privately held biopharmaceutical company focused on developing and commercializing antibiotics to treat life-threatening infections.